Device Trial Radar · NCT06654466
Closing the GAPS: Guideline Adherence, Prevention and Surveillance in Hereditary Cancer
Last checked: Nov 19, 2026Latest source record: Jul 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
100
Actual
Start
Feb 10, 2026
Primary completion
Mar 2027
Study completion Sep 2027
Sponsor
- Lead sponsor
- Nest GenomicsNot on our public-company list
- Sponsor type
- Industry
- Collaborators
- Dana-Farber Cancer Institute; National Human Genome Research Institute (NHGRI)
- First posted
- Oct 23, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Supportive care
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years, up to 49 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to see if a software platform can improve cancer screening in young adults with genetic risk for cancer. The trial will also help improve the software platform (Nest). The main questions it aims to answer are: * Do Nest users know more about their cancer risks and recommended care than non-users? * Do Nest users have less psychological distress than non-users? * Do Nest users share cancer risks with family and other doctors more than non-users? * Are Nest users more likely than non-users to have up-to-date care plans? Researchers will compare Nest users to non-users to see if the Nest users are more likely to do recommended cancer screening. Participants will: * Have a genetic counseling or follow up visit * Take a post-visit survey * Intervention arm only: use the Nest Patient Navigator * Complete screening and follow-up care recommended by doctors
Conditions
- Hereditary Cancer Syndromes
- Clinical Decision Support
Interventions
Nest, an electronic medical record (EMR)-integrated software platform to deliver longitudinal, genetics-based care at scale.Device
The Nest software platform includes the Nest Care Studio, Nest Patient Navigator and the Analytics Dashboard. Nest Care Studio is a clinician facing portal that can be used standalone or electronic medical record (EMR) integrated. Care Studio enables clinicians to effectively manage patients' genetic information over time. Clinicians can see a list of patients that meet criteria for testing, run risk assessment calculations, order genetic tests, manage patients based on results and view education modules.The Nest Patient Navigator is a secure mobile device accessible platform that provides a centralized location for patients to store, manage, and follow-up with their genetic results. The Analytics Dashboard is an interactive dashboard that can track outcomes of genomic programs and trigger interventions to optimize them.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Acceptability of Intervention Measure (AIM)Time frame: within 7 days of visit
- Gist Comprehension of Genetic Cancer RiskTime frame: Baseline, within 7 days of visit
- Knowledge of Cancer ScreeningTime frame: Baseline, within 7 days of visit
2 more outcomes with a free account
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Dana Farber Cancer Institute
Boston, Massachusetts
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.